In a significant milestone for skincare and sun protection, the Food and Drug Administration (FDA) has granted approval for bemotrizinol, a sunscreen ingredient that effectively blocks both UVA and UVB rays, marking the first approval of a new chemical UV filter in nearly 30 years. This decision has been met with enthusiasm from experts within the dermatological community, who view it as a transformative development in sun safety.
Dr. Heather Rogers, a dermatologist based in Seattle and a fellow of the American Academy of Dermatology, expressed her excitement, stating, “This is a very big deal.” She emphasized that bemotrizinol fulfills multiple requirements that dermatologists and consumers have been seeking in sunscreen formulations.
One of the primary benefits of bemotrizinol is its comprehensive protection against both UVA and UVB rays. While existing sunscreens in the U.S. provide adequate defense against UVB rays—the shorter wavelengths responsible for sunburn—most previously available ingredients were not as effective at blocking UVA rays, which contribute to skin aging and an increased risk of skin cancer. Current chemical filters, such as avobenzone, are known to degrade quickly when exposed to sunlight, leading to diminished protection and potential skin irritation from byproducts.
In contrast, bemotrizinol is not only stable under UV exposure but also offers sustained protection for longer periods, meaning that users can count on its efficacy even if they delay reapplication beyond the recommended two-hour window. However, dermatologists still advise that sunscreen should be reapplied every two hours during sun exposure.
Bemotrizinol has a long history of use in sunscreens in Europe and Asia, where it has been a staple for over two decades. The lengthy approval process in the U.S. reflects the rigorous testing standards set for over-the-counter drugs, necessitating extensive safety and efficacy studies. This is evidenced by the considerable investment made by the European company DSM-Firmenich, which reportedly spent over $18 million in its bid for FDA approval.
Importantly, the safety profile of bemotrizinol is well-documented, with studies indicating that it poses minimal risks, such as reproductive harm. Clinical trials have shown it to be non-irritating to the skin, even after repeated applications, making it a safer choice for long-term use. Its larger molecular size also means it is less likely to be absorbed into the bloodstream, a concern raised about some other chemical UV filters on the market.
Bemotrizinol’s development is expected to lead to better-looking sunscreens. Traditional mineral sunscreens, which utilize zinc oxide and titanium dioxide, provide similar protection but often leave a visible white cast on the skin—an issue particularly noticeable for individuals with darker skin tones. Being transparent upon application, bemotrizinol presents a solution to this aesthetic challenge while maintaining high standards of sun protection.
The exclusive rights to market bemotrizinol in the U.S. for the next 18 months belong to DSM-Firmenich, which plans to sell the ingredient under the brand name Parsol Shield. Consumers can anticipate the arrival of sunscreen products containing this innovative ingredient on American store shelves by September. This advancement suggests a promising future for more effective and cosmetically appealing sun protection options, greatly enhancing public health efforts against skin cancer.
